Scopia Capital Management

The firm is run by co-founders Matt Sirovich and Jeremy Mindich, both of whom serve as portfolio managers and sit on the investment committee. They worked together at Kingdon Capital before launching Scopia in 2001. There is no public succession plan, and the two principals remain the key decision-makers.

Scopia determined that its strategy — concentrated, fundamentally-driven long-short equity — performed best with a leaner asset base. By returning external capital starting around 2018–2019, it preserved capacity for its highest-conviction ideas and increased alignment with remaining partners and employee capital (per Bloomberg, 2020). The decision placed capacity discipline above fee maximization.

Scopia runs a concentrated long-short equity fund with 25–35 core positions, heavily focused on TMT and healthcare. It typically operates with net exposure between 40% and 60%. The approach is bottom-up, fundamental research-driven, and occasionally includes constructive shareholder engagement.

Scopia is not primarily an activist fund. While it will occasionally engage with management teams on value-unlocking initiatives, its default posture is fundamental stock selection. 13F filings historically show large, concentrated bets in names like Charter Communications and Allergan, but public activist campaigns are rare.

Scopia's deliberate capital return to external limited partners suggests the firm has been operating as a largely closed vehicle since roughly 2019. The current balance of partner and employee capital versus external LP capital has not been publicly disclosed, and the firm does not publicly market for new allocations.